Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Tenaya Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401 Anticipated in Second Half 2023 Second Quarter Cash and Investments of $152 Million; Runway to Fund Operations into First Half 2025 SOUTH SAN FRANCISCO, Calif., August 9, 2023 -- Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended June 30, 2023. “We are looking ahead..."
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Certificate of Amendment to THE Amended and Restated Certificate of Incorporation of TENAYA THERAPEUTICS, Inc.",
"TENAYA THERAPEUTICS, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION 1. Introduction. The purpose of this Tenaya Therapeutics, Inc. Executive Change in Control and Severance Plan is to provide assurances of specified benefits to certain employees of the Company whose employment could be being involuntarily terminated other than for death, Disability, or Cause or voluntarily terminated for Good Reason under the circumstances described in the Plan. This Plan is an “employee welfare benefit plan,” as defined in Section 3 of ERISA. This document is both the written instrument under which the Plan is maintained and the required summary plan description for the Plan. 2. Important Terms. The following words and phrases, when the initial letter of the..."
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson Join Scientific Advisory Board Announces Formation of Technical Advisory Board with Deep Expertise in Gene Therapy Manufacturing SOUTH SAN FRANCISCO, Calif., May 10, 2023 -- Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the first quarter ended March 31, 2023. “Tenaya is making ..."
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/08/2023 10-K Annual Report for the period ended December 31, 2022
03/08/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update TN-201 IND Cleared in January; Plan to Begin Phase 1b Dosing in MYBPC3-associated HCM Patients in Third Quarter 2023 Dosing Commenced in Multiple-Ascending Dose Stage of First-In-Human Clinical Trial of TN-301; Data Anticipated in Second Half 2023 2022 Year End Cash and Investments of $204 Million; Runway to Fund Operations into First Half 2025 South San Francisco, Calif. – March 8, 2023 – Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2022 and p..."
02/21/2023 SC 13D/A COLUMN GROUP III, LP reports a 17.8% stake in TENAYA THERAPEUTICS, INC.
02/14/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in Tenaya Therapeutics, Inc.
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 6.7% stake in TENAYA THERAPEUTICS INC
02/09/2023 SC 13G/A FMR LLC reports a 4.2% stake in TENAYA THERAPEUTICS INC
12/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors SOUTH SAN FRANCISCO, Calif., – December 7, 2022 – Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases. “We are pleased to welcome Ms. Burroughs to the Tenaya Board. Her substantial and diverse industry experience in the development and commercial launch of innovative products will be directly relevant..."
12/07/2022 SC 13D/A Casdin Capital, LLC reports a 9.9% stake in Tenaya Therapeutics, Inc.
12/01/2022 SC 13D COLUMN GROUP III, LP reports a 15% stake in TENAYA THERAPEUTICS, INC.
11/28/2022 SC 13D/A Casdin Capital, LLC reports a 9.9% stake in Tenaya Therapeutics, Inc.
11/17/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, among Tenaya Therapeutics, Inc. and the Representatives",
"Form of Pre-Funded Warrant",
"Opinion of Wilson Sonsini Goodrich & Rosati, P.C",
"Tenaya Therapeutics Announces Pricing of Public Offering"
11/17/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/16/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/11/2022 SC 13G/A FMR LLC reports a 7.6% stake in TENAYA THERAPEUTICS INC
08/18/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/17/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/10/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, between Tenaya Therapeutics, Inc. and SVB Securities LLC"
08/10/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline Programs and Capsid Engineering Efforts South San Francisco, Calif. – Aug. 10, 2022—Tenaya Therapeutics, Inc. , a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended June 30, 2022. “Tenaya continues to make strides forward in our transition to becoming a fully integrated clinical-stage company and continues to invest ..."
06/10/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/11/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy